Eli Lilly Eyes €15 Billion Abivax Acquisition Amid Drug Success

Abivax shares surge 4% on reports of Eli Lilly's €15B buyout interest. The French biotech's experimental ulcerative colitis drug obefazimod attracts big pharma attention after trial success.